BioLife Solutions (NASDAQ:BLFS) Trading Down 2.7%
BioLife Solutions (NASDAQ:BLFS) Trading Down 2.7%
Shares of BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) were down 2.7% during trading on Friday . The company traded as low as $25.68 and last traded at $25.97. Approximately 3,826 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 263,292 shares. The stock had previously closed at $26.70.
在周五的交易中,BioLife Solutions,Inc.(纳斯达克代码:BLFS-GET Rating)的股价下跌了2.7%。该公司股价低至25.68美元,最新报25.97美元。午盘成交量约为3,826股,较263,292股的日均成交量下降99%。该股此前收盘价为26.70美元。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Several brokerages recently issued reports on BLFS. B. Riley decreased their price objective on BioLife Solutions from $48.00 to $34.00 in a research report on Tuesday, May 17th. Cowen decreased their price objective on BioLife Solutions to $29.00 in a research report on Monday, August 15th. One investment analyst has rated the stock with a sell rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, BioLife Solutions presently has an average rating of "Moderate Buy" and an average price target of $31.25.
几家券商最近发布了关于BLFS的报告。B.莱利在5月17日星期二的一份研究报告中将他们对BioLife Solutions的目标价从48.00美元下调至34.00美元。考恩在8月15日星期一的一份研究报告中将他们对BioLife Solutions的目标价格下调至29.00美元。一名投资分析师对该股的评级为卖出,三名分析师对该公司股票的评级为买入。根据MarketBeat.com的数据,BioLife Solutions目前的平均评级为“中等买入”,平均目标价为31.25美元。
BioLife Solutions Price Performance
BioLife解决方案性价比
The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.54 and a current ratio of 3.55. The company has a 50-day moving average of $20.70 and a 200-day moving average of $18.37. The firm has a market capitalization of $1.13 billion, a price-to-earnings ratio of -11.83 and a beta of 1.91.
该公司的负债权益比为0.02,速动比率为2.54,流动比率为3.55。该公司的50日移动均线切入位在20.70美元,200日移动均线切入位在18.37美元。该公司的市值为11.3亿美元,市盈率为-11.83倍,贝塔系数为1.91。
Insiders Place Their Bets
内部人士下注
Institutional Investors Weigh In On BioLife Solutions
机构投资者对BioLife解决方案发表意见
Several large investors have recently made changes to their positions in the stock. Captrust Financial Advisors boosted its holdings in shares of BioLife Solutions by 714.2% in the 2nd quarter. Captrust Financial Advisors now owns 3,949 shares of the medical equipment provider's stock valued at $55,000 after buying an additional 3,464 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of BioLife Solutions by 17.5% in the 2nd quarter. Legal & General Group Plc now owns 78,876 shares of the medical equipment provider's stock valued at $1,089,000 after buying an additional 11,762 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of BioLife Solutions by 7.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 78,871 shares of the medical equipment provider's stock valued at $1,089,000 after buying an additional 5,414 shares during the last quarter. Macquarie Group Ltd. boosted its holdings in shares of BioLife Solutions by 1.1% in the 2nd quarter. Macquarie Group Ltd. now owns 73,437 shares of the medical equipment provider's stock valued at $1,014,000 after buying an additional 766 shares during the last quarter. Finally, First Republic Investment Management Inc. boosted its holdings in shares of BioLife Solutions by 7.6% in the 2nd quarter. First Republic Investment Management Inc. now owns 24,084 shares of the medical equipment provider's stock valued at $333,000 after buying an additional 1,705 shares during the last quarter. Institutional investors and hedge funds own 86.69% of the company's stock.
几家大型投资者最近改变了他们在该股的头寸。CapTrust Financial Advisors在第二季度将其持有的BioLife Solutions股票增加了714.2%。CapTrust Financial Advisors在上个季度又购买了3464股后,现在拥有3949股这家医疗设备提供商的股票,价值5.5万美元。Legal&General Group Plc在第二季度增持了BioLife Solutions的股票17.5%。Legal&General Group Plc现在拥有这家医疗设备提供商78,876股票,价值1,089,000美元,上个季度又购买了11,762股票。高盛股份有限公司在第二季度增持了BioLife Solutions的股份7.4%。高盛股份有限公司现在持有这家医疗设备供应商78,871股股票,价值1,089,000美元,该公司在上个季度又购买了5,414股。第二季度,麦格理集团(Macquarie Group Ltd.)增持BioLife Solutions的股票1.1%。麦格理集团(Macquarie Group Ltd.)目前持有73,437股这家医疗设备供应商的股票,价值1,014,000美元,该公司在上个季度又购买了766股。最后,First Republic Investment Management Inc.在第二季度增持了BioLife Solutions的股票7.6%。First Republic Investment Management Inc.现在持有这家医疗设备提供商24,084股股票,价值33.3万美元,该公司在上个季度又购买了1,705股。机构投资者和对冲基金持有该公司86.69%的股票。
BioLife Solutions Company Profile
BioLife Solutions公司简介
(Get Rating)
(获取评级)
BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
BioLife Solutions,Inc.为美国、加拿大、欧洲、中东、非洲和国际上的细胞和基因治疗行业开发、制造和提供生物生产工具和服务。该公司的产品用于基础和应用研究,以及基于生物的疗法的商业制造。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免费获取StockNews.com关于BioLife解决方案的研究报告(BLFS)
- MarketBeat:回顾一周9/5-9/9
- 为网络安全股创纪录的季度做准备
- 汽车市场正在缓慢复苏,这些股票可能表现优异
- DocuSign是否即将发生重大逆转?
- 石油和天然气股票:投资可再生能源的安全途径
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
每日收到有关BioLife解决方案的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对BioLife Solutions和相关公司的最新新闻和分析师评级的每日简要摘要。